Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Venous Thromboembolism — Anticoagulation

First-line Second-line SECOND-LINE Acute VTE (DVT / PE) Most patients Cancer-associated Special situations Preferred DOAC — apixaban AMPLIFY ↗ Preferred DOAC — rivaroxaban EINSTEIN ↗ Onc VTE DOAC or LMWH Hokusai-Cancer ↗ APS / severe renal Warfarin (VKA) avoid DOAC in triple-+ APS Duration 3 mo (provoked) vs extended if unprovoked / ongoing risk